semaglutide
Wegovy Approved to Treat MASH With Moderate to Advanced Fibrosis
The FDA has approved semaglutide in conjunction with diet and exercise for the treatment of MASH with moderate to ...
AUGUST 20, 2025
Insurance Restrictions, Low Reimbursement Hitting Pharmacies on GLP-1s
Despite increasing demand for GLP-1 drugs, these medications are often excluded from coverage in employer health ...
MAY 28, 2025
FDA Declares End to Semaglutide Shortage; Clock Ticking on Compounded Versions
In the wake of the FDA’s Feb. 21, 2025 announcement declaring an end to the semaglutide shortage, ...
FEBRUARY 24, 2025
How a GLP-1 ‘Shadow System’ Puts Patients’ Safety at Risk
Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonist drugs are evading FDA scrutiny and ...
NOVEMBER 7, 2024
Study Finds GLP-1s Safe and Effective For Managing Obesity in Patients With IBD
GLP-1s are well tolerated and effective for weight loss in patients with IBD, according to new research
NOVEMBER 6, 2024
'A War Brewing’ Between GLP-1 Manufacturers and Compounders
Are glucagon-like peptide-1 drugs like semaglutide and tirzepatide too complex for 503A and 503B compounders to ...
NOVEMBER 1, 2024
'Tail Period' for Compounders Could Ease Weight-Loss Rx Shortages
Compounder should be allowed to produce products beyond the FDA’s current hard compounding cut-off. The ...
OCTOBER 10, 2024
Machine Learning Can Predict Best Responders to GLP-1s
Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond ...
SEPTEMBER 20, 2024
Semaglutide Improves Kidney Disease and Diabetes Outcomes
Treating patients with type 2 diabetes and chronic kidney disease with the glucagon-like peptide-1 (GLP-1) receptor ...
JULY 3, 2024
Report: GLP-1 Adherence Rates Lower Than Expected
Although more than 90% of patients adhered to GLP-1 agonists through the end of clinical trials, new data suggest ...
MAY 23, 2024
Employer Health Plans Mull Over Coverage of GLP-1 Agonists for Weight Loss
The International Foundation of Employee Benefit Plans published a report about trends in employee coverage of ...
MARCH 18, 2024
Weight Loss Medications Pose New Challenges for Benefit Leaders
With the surge in popularity of the GLP-1 receptor agonists Saxenda and Wegovy, and the recent FDA approval of ...
MARCH 5, 2024
